Rocco Piazza

Recurrent SETBP1 mutations in atypical chronic myeloid leukemia

Rocco Piazza, Simona Valletta, Nils Winkelmann et al. · Nature Genetics · 2012 · 422 citations · Full text

Hematological Malignancy, Hematology, Medicine +4

<i>In vitro</i> and <i>In vivo</i> Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells

Miriam Puttini, Addolorata Maria Luce Coluccia, Frank Boschelli et al. · Cancer Research · 2006 · 368 citations

Hematological Malignancy, Cell Signaling, Ski-606 Activity +13

Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase–Positive Lymphoma Patients

Carlo Gambacorti‐Passerini, Francesca Farina, Alessandra Stasia et al. · JNCI Journal of the National Cancer Institute · 2014 · 275 citations

Hematological Malignancy, Lymphoid Neoplasia, Alk+ Lymphoma Patients +9

Age and d<scp>PCR</scp> can predict relapse in <scp>CML</scp> patients who discontinued imatinib: The <scp>ISAV</scp> study

Silvia Mori, Elisabetta Vagge, Philipp le Coutre et al. · American Journal of Hematology · 2015 · 207 citations · Full text

SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub

Rocco Piazza, Vera Magistroni, Sara Redaelli et al. · Nature Communications · 2018 · 152 citations · Full text